Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with ...
In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), ...
The 19th G20 Summit is being held in Rio de Janeiro, Brazil, from November 18 to 19. Chinese President Xi Jinping said at the summit that China has announced the decision to give all the least ...
Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...
(Reuters) - Singapore's Keppel will spin off its data centre joint venture (JV) to unit Keppel DC REIT for a total gross ...
It's no secret that the venture capital industry is facing a liquidity crisis as IPOs and other exits remain few and far ...
Analysts Predict a $102 Target for Viking Therapeutics Inc (VKTX) Stock—What Could Drive It There?
On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback